Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Presentation ACC 2024

Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery

Presenter: Andre Lamy

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Presentation ACC 2024

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

Presenter: Javed Butler

April 06, 2024

Presentation ACC 2024

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Presenter: C. Michael Gibson

April 06, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Heavy Drinking May Contribute to CHD Risk in Young Women

L.A. McKeown

April 02, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

Advertisement

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Need a Statin for Primary Prevention? There’s an App for That

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Heavy Drinking May Contribute to CHD Risk in Young Women

What’s Going to Be Hot at ACC 2024

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content